Version 1.3 of the semgine sciPlorer® enables scientists to have terms explained to them simply using brief, concise collections of facts. At the same time, the results filtering has been fundamentally expanded, so more and better results can now be achieved.
"The reports now available, with their brief, clear facts, allow for very fast and effortless information acquisition and are a clear unique selling proposition for the semgine sciPlorer®" explains Dr Martin C. Hirsch, CEO of semgine GmbH. "With the extraction of facts from the Internet, we are consistently expanding the semgine sciPlorer®, developing it into a semantic search engine for the biomedical sciences. Weâve brought Web 3.0 a step closer for the biomedical sciences."
The semgine sciPlorer® is based on a completely new approach, which applies the principles of cognitive neuroscience to information processing. While conventional search engines create a normal word-based, full-text index of documents, semgine® builds up a semantic index, enabling users to accurately pinpoint individual facts in documents.
"We've really 'hit a nerve' in the community with the semgine sciPlorer®" notes Dr Thomas Meyer, Sales Manager Life Sciences at semgine GmbH. "A test customer summed it up aptly: With the semgine sciPlorer® you've developed an excellent information retrieval solution with a technically perfected refinement strategy."
About semgine GmbH
semgine GmbH (www.semgine.com) develops software frameworks for building semantic knowledge assistants for the Web 3.0. Its unique approach, utilising Brainlike Information Management, is derived from current insights into cognitive neurosciences, forming the basis for cutting-edge software technology designed to retrieve complex information relationships quickly and accurately.
The company was founded in 1994 by Dr Martin C. Hirsch, neurobiologist and grandson of physicist and Nobel Laureate Werner Heisenberg. semgine GmbH focuses on the life sciences sector and its customers include Altana Pharma AG, BBraun AG, Honda Research Institute Europe and Sanofi-Aventis Deutschland GmbH. The core technology is funded by the German Ministry of Education and Research and, within the BioSim project, by the 6th Framework Programme of the European Commission.